Drug manufacturers Moderna and Merck say a personalized mRNA cancer vaccine plus a drug called Keytruda reduced the return ...

An experimental mRNA vaccine allowed people with high-risk melanoma to live longer, cancer-free, in a large, closely watched ...

The combined drug works by nudging the body’s own immune system to make proteins that attack and destroy melanoma cells ...

Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines.

Drug company stocks soared following news that Moderna and Merck’s experimental mRNA-based cancer vaccine succeeded in a late ...

Moderna and Merck said on Wednesday (August 19) that a personalized mRNA cancer vaccine reduced the risk of recurrence and ...

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment ...

Combining a vaccine and immunotherapy approach could open new ways to treat cancer.

CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big ...

In light of recent wins for mRNA vaccine makers, UCSC RNA Center Co-Director Jeremy Sanford describes the versatility of the ...

In a new study, scientists from Johns Hopkins Medicine report that an experimental mRNA-based platform has the potential to ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 20% in the morning session after investors took profits as the ...